Article Sidebar

PDF
Date Published: 10/12/2025
Abstract Views: 11
Views PDF: 1
DOI: 10.56535/jmpm.v50si4.1634
Issue
Vol. 50 No. si4 (2025): JOURNAL OF MILITARY PHARMACO-MEDICINE - SPECIAL ISSUE 12/2025
Section
Special issue celebrating the 75th anniversary of Military Hospital 103
How to Cite
Nguyen, C. P., Vu, A. H., & Ho, V. H. (2025). ASSESSMENT OF THE IMPACT OF COMORBIDITIES ON TREATMENT PLAN ADHERENCE IN LUNG CANCER PATIENTS. Journal of Military Pharmaco-medicine, 50(si4), 385-393. https://doi.org/10.56535/jmpm.v50si4.1634

ASSESSMENT OF THE IMPACT OF COMORBIDITIES ON TREATMENT PLAN ADHERENCE IN LUNG CANCER PATIENTS

Chau Phong Nguyen1, , Anh Hai Vu1, Viet Hoanh Ho1
1 Trung tâm Ung bướu, Bệnh viện Quân y 103, Học viện Quân y

Main Article Content

Abstract

Objectives: To determine the prevalence of comorbidities and their impact on treatment plan adherence among patients with lung cancer. Methods: A retrospective and prospective, cross-sectional study was conducted on 491 lung cancer patients (a mean age of 60 ± 10 years) from April 2024 to April 2025 at the Oncology Center, Military Hospital 103. Results: The prevalence of patients with at least 1 comorbidity was 62.53%. Gastrointestinal disorders (esophagitis, peptic ulcer disease) were the most common (36.46%) and were significantly more frequent in patients ≤ 60 years compared to those > 60 years (p < 0.05). In contrast, cardiovascular diseases and diabetes mellitus were more prevalent in patients > 60 years, who also had a higher mean number of comorbidities. Overall, 62.21% of patients with comorbidities failed to adhere to the planned treatment regimen. Among these, failure to adhere chemotherapy plan accounted for the highest proportion (52.88%), and 100% of patients with ≥ 4 comorbidities failed to complete their treatment regimen. Conclusion: Comorbidities are common in lung cancer patients and have a significant impact on treatment plan adherence. 

Keywords

Comorbidities, Lung cancer, Treatment plan

Article Details

References

1. World Health Organization. Lung Cancer Fact Sheet. Geneva: WHO; 26 June 2023. Available from the WHO website.
2. Nguyễn Thị Nga, Lê Thị Vũ Huyền, Nguyễn Thị Thu Thủy, Trần Thị Thanh Hương, Phạm Tường Vân. Một số đặc điểm dịch tễ và mô bệnh học ung thư phổi tại Hà Nội, 2015-2019. Tạp chí Y học Cộng đồng. 2023; 64(3): DOI:10.52163/yhc.v64i3.646.
3. American Cancer Society. Cancer.org. Atlanta: ACS; 2023. Available from: https://www.cancer.org [7/2025]
4. Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021; 25(1):45-52. DOI:10.5114/wo.2021.103059.
5. Fowler H, Belot A, Ellis L, et al. Comorbidity prevalence among cancer patients: A population-based cohort study of four cancers. BMC Cancer. 2020; 20(1):2. DOI:10.1186/s12885-019-6472-9.
6. Borg M, Løkke A, Ibsen R, Hilberg O. Four decades of lung cancer: Trends in comorbidities and causes of death in a nationwide Danish cohort. Eur J Cancer. 2025; 218:115303. DOI:10.1016/j.ejca.2025.115303.
7. Islam KM, Stevens A, Ganti AK. Survival trends for patients with small cell lung cancer (SCLC) in the United States: Analysis of the SEER Database. JSM Clin Oncol Res. 2020; 8(1):1062.
8. Vrinzen CEJ, Delfgou L, Stadhouders N, et al. A systematic review and multilevel regression analysis reveals the comorbidity prevalence in cancer. Cancer Res. 2025; 83(7):1147-1157. DOI:10.1158/0008-5472.CAN-22-1336.
9. Leduc C, Antoni D, Charloux A, Falcoz PE, Quoix E. Comorbidities in the management of patients with lung cancer. Eur Respir J. 2017; 49(3):1601721. DOI:10.1183/13993003.01721-2016.